Boehringer Ingelheim is a pretty familiar name to people who follow mobile health moves from pharma companies. The large, privately-owned German firm has been involved in pilots with game developer Ayogo, smart pill bottle maker AdhereTech, and now-defunct behavior change platform Healthrageous.
While its partners have talked up these pilots, up until now the company itself has been pretty quiet about its strategies in testing out innovative health technology.
At Health 2.0 last week in Santa Clara, California, Larry Brooks, the director of the New Business Model and Healthcare Innovation group at Boehringer Ingelheim took the stage with Propeller Health CEO David Van Sickle to talk about a newly announced pilot of Propeller’s technology.
“About three years ago, the company said patients, especially those with high risk diseases, shouldn’t be treated with just medications,” Brooks said. “They should be treated more comprehensively. So we started the New Business Model and Healthcare Innovation group, positioned within our business development and licensing, because just as we have folks looking for new molecular markers, we really wanted to find technology that we thought was going to shape the broader healthcare delivery and financing system and have an impact on Boehringer and our prescription medication. So it continues to be a learn-by-doing type of group that continuously is signing customer-based agreements to validate whether there’s a particular technology we should be looking for, even if it’s in the longer two to five year range, and not necessarily in the short term.” Keep reading>>